As of 2025-05-29, the Intrinsic Value of ACADIA Pharmaceuticals Inc (ACAD) is 28.92 USD. This Acadia valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 22.02 USD, the upside of ACADIA Pharmaceuticals Inc is 31.30%.
The range of the Intrinsic Value is 24.55 - 36.33 USD
Based on its market price of 22.02 USD and our intrinsic valuation, ACADIA Pharmaceuticals Inc (ACAD) is undervalued by 31.30%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 24.55 - 36.33 | 28.92 | 31.3% |
| DCF (Growth 10y) | 27.71 - 39.43 | 32.09 | 45.7% |
| DCF (EBITDA 5y) | 26.76 - 29.10 | 27.63 | 25.5% |
| DCF (EBITDA 10y) | 29.74 - 33.17 | 31.15 | 41.5% |
| Fair Value | 33.83 - 33.83 | 33.83 | 53.65% |
| P/E | 23.55 - 36.63 | 29.41 | 33.6% |
| EV/EBITDA | 13.98 - 30.54 | 20.16 | -8.4% |
| EPV | (0.14) - (0.90) | (0.52) | -102.3% |
| DDM - Stable | 7.85 - 16.63 | 12.24 | -44.4% |
| DDM - Multi | 9.82 - 16.59 | 12.38 | -43.8% |
| Market Cap (mil) | 3,684.61 |
| Beta | 1.19 |
| Outstanding shares (mil) | 167.33 |
| Enterprise Value (mil) | 2,928.61 |
| Market risk premium | 4.60% |
| Cost of Equity | 11.69% |
| Cost of Debt | 5.00% |
| WACC | 8.27% |